We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Efficacy and Tolerability of Baclofen for Alcohol Dependence

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 8, 2009
Last Update Posted: September 14, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of North Carolina, Chapel Hill
February 7, 2008
April 8, 2009
September 14, 2012
April 2005
May 2007   (Final data collection date for primary outcome measure)
% heavy drinking days [ Time Frame: 2 years ]
Same as current
Complete list of historical versions of study NCT00877734 on ClinicalTrials.gov Archive Site
  • % relapse [ Time Frame: 2 years ]
  • % abstinent days [ Time Frame: 2 years ]
  • depression symptoms [ Time Frame: 2 years ]
  • anxiety symptoms [ Time Frame: 2 years ]
Same as current
Not Provided
Not Provided
Efficacy and Tolerability of Baclofen for Alcohol Dependence
Phase IIIa Trial of Baclofen for Alcohol Dependence
This is a study of the efficacy and safety of baclofen for alcohol dependence. 80 outpatient subjects with DSM-IV alcohol dependence will be randomized to 10 mg three times a day (tid) baclofen or tid placebo. An effort will be made to recruit 40 men and 40 women. Subjects will receive BRENDA counseling over the 12 weeks of the trial. The Timeline Followback (TLFB) method will be used to assess drinking patterns. The primary outcome is % heavy drinking during the trial.
The study will explore the efficacy and tolerability of a 12-week regimen of 10 mg t.i.d. baclofen vs. placebo in conjunction with behavioral therapy for reducing heavy drinking in 80 alcohol dependent individuals. Prior studies (Addolorato et al. 2000, 2002; Flannery et al., 2004) have found that baclofen reduces self-reported anxiety and craving; therefore, the proposed study also will assess baclofen's ability to reduce symptoms of these affective states. Furthermore, in our pilot study (Flannery et al, 2004), women appeared to respond more consistently than men, and therefore the study will also be balanced by gender.
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Alcohol Dependence
  • Drug: baclofen
    10 mg Baclofen administered tid for 11 weeks
    Other Name: Lioresal
  • Drug: placebo
    Placebo administered tid for 11 weeks
  • Behavioral: BRENDA counseling
  • Experimental: 1
    • Drug: baclofen
    • Behavioral: BRENDA counseling
  • Placebo Comparator: 2
    • Drug: placebo
    • Behavioral: BRENDA counseling
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2007
May 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria

  1. Men and women between the ages of 18 and 60 meeting DSM-IV criteria for current alcohol dependence.
  2. Must have had at least 2 heavy drinking days (men > 5 drinks/days; women > 4 drinks/day) per week, on average and an average overall consumption of 21 drinks/week or more for men and 14 drinks/week or more for women during the 4 weeks prior to screening.
  3. Able to understand and sign written informed consent.
  4. Must be willing to refrain from drinking for three days prior to randomization day.
  5. Express a desire to achieve abstinence or to greatly reduce alcohol consumption.
  6. Must have a stable residence and be able to identify an individual who could locate subject if needed.

Exclusion Criteria

  1. Clinically significant medical disease that might interfere with the evaluation of the study medication or present a safety concern (e.g., cirrhosis, kidney impairment, unstable hypertension, hypotension, diabetes mellitus, seizure disorder).
  2. Clinically significant psychiatric illness including any psychotic disorder, bipolar disorder, or severe depression; suicidal ideation; substance use disorder other than alcohol or nicotine dependence or cannabis abuse.
  3. History of complicated alcohol withdrawal, i.e. withdrawal seizure or delirium tremens.
  4. Concurrent use of any psychotropic medication including antidepressants, mood stabilizers, antipsychotics, anxiolytics, stimulants, or hypnotics. However, subjects who have been on stable doses of the antidepressants fluoxetine, sertraline, paroxetine, citalopram, ecitalapram, trazodone or venlafaxine for two months will be eligible. Subjects who have been taking benzodiazepines for alcohol detoxification will be required to have a washout period of at least five half-lives (approximately 5 days) from those medications before being randomized.
  5. Concurrent use of anticonvulsants, insulin, or oral hypoglycemics.
  6. AST, or ALT > 3 times Upper Limit of Normal (ULN), or bilirubin > ULN, or creatinine > ULN.
  7. Positive urine toxicology screen with the exception of cannabis. Individuals with positive cannabis screens will be excluded only if they have a history of cannabis dependence.
  8. Pregnant women and women of childbearing potential who do not practice a medically acceptable form of birth control (oral or depot contraceptive, or barrier methods such as diaphragm or condom with spermicidal).
  9. Women who are breastfeeding.
  10. Individuals requiring inpatient treatment or more intense outpatient treatment for their alcohol dependence.
  11. Participation in any clinical trial within the last 60 days.
  12. Court-mandated participation in alcohol treatment or pending incarceration.
Sexes Eligible for Study: All
21 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
James C. Garbutt, MD/Principal Investigator, UNC Department of Psychiatry
University of North Carolina, Chapel Hill
Not Provided
Principal Investigator: James C Garbutt, MD UNC Department of Psychiatry
University of North Carolina, Chapel Hill
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP